Loxo Oncology at Lilly
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Loxo Oncology at Lilly
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.
White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening.
- Other Names / Subsidiaries
- Loxo Oncology, Inc.